Cargando…

CK1δ as a potential therapeutic target to treat bladder cancer

Bladder cancer is the second most common genitourinary malignancy in the world. However, only immune-checkpoint inhibitors and erdafitinib are available to treat advanced bladder cancer. Our previous study reported that 4-((4-(4-ethylpiperazin-1-yl) phenyl)amino)-N-(3,4,5-trichlorophenyl)-7H-pyrrolo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yu-Chen, Chen, Mei-Chuan, Hsieh, Tsung-Han, Liou, Jing-Ping, Chen, Chun-Han
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185098/ https://www.ncbi.nlm.nih.gov/pubmed/32282334 http://dx.doi.org/10.18632/aging.102966

Ejemplares similares

CK1δ in lymphoma: gene expression and mutation analyses and validation of CK1δ kinase activity for therapeutic application
por: Winkler, B. Sophia, et al.
Publicado: (2015)

Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells
por: Chen, Chun-Han, et al.
Publicado: (2019)

Stellettin B Induces Cell Death in Bladder Cancer Via Activating the Autophagy/DAPK2/Apoptosis Signaling Cascade
por: Chang, Chun-Han, et al.
Publicado: (2023)

CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target
por: Chua, Melissa M.J., et al.
Publicado: (2017)

Potential Therapeutic Roles of Tanshinone IIA in Human Bladder Cancer Cells
por: Chiu, Sheng-Chun, et al.
Publicado: (2014)

CK1δ-Derived Peptides as Novel Tools Inhibiting the Interactions between CK1δ and APP695 to Modulate the Pathogenic Metabolism of APP
por: Roth, Aileen, et al.
Publicado: (2021)

CK1δ and CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma
por: Burger, Karen L., et al.
Publicado: (2023)

Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment
por: Hsieh, Tsung-Han, et al.
Publicado: (2021)

Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management
por: Lian, Haiwei, et al.
Publicado: (2019)

Targeting of the circadian clock via CK1δ/ε to improve glucose homeostasis in obesity
por: Cunningham, Peter S., et al.
Publicado: (2016)

Therapeutic targeting of CK2 in acute and chronic leukemias
por: Buontempo, F, et al.
Publicado: (2018)

Potential therapeutic effects of N-butylidenephthalide from Radix Angelica Sinensis (Danggui) in human bladder cancer cells
por: Chiu, Sheng-Chun, et al.
Publicado: (2017)

Protein kinase CK2: a potential therapeutic target for diverse human diseases
por: Borgo, Christian, et al.
Publicado: (2021)

Casein Kinase 1 Family Member CK1δ/Hrr25 Is Required for Autophagosome Completion
por: Li, Yuting, et al.
Publicado: (2020)

CRISPR-mediated gene targeting of CK1δ/ε leads to enhanced understanding of their role in endocytosis via phosphoregulation of GAPVD1
por: Guillen, Rodrigo X., et al.
Publicado: (2020)

CK1δ Kinase Activity Is Modulated by Chk1-Mediated Phosphorylation
por: Bischof, Joachim, et al.
Publicado: (2013)

Comprehensive Characterization of CK1δ-Mediated Tau Phosphorylation in Alzheimer’s Disease
por: Roth, Aileen, et al.
Publicado: (2022)

Neurite Outgrowth of Mature Retinal Ganglion Cells and PC12 Cells Requires Activity of CK1δ and CK1ε
por: Bischof, Joachim, et al.
Publicado: (2011)

Protein Kinase CK2 and Its Potential Role as a Therapeutic Target in Huntington’s Disease
por: White, Angel, et al.
Publicado: (2022)

Interaction of CK1δ with γTuSC ensures proper microtubule assembly and spindle positioning
por: Peng, Yutian, et al.
Publicado: (2015)

MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-γ-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells
por: Chen, Mei-Chuan, et al.
Publicado: (2019)

CK1δ stimulates ubiquitination‐dependent proteasomal degradation of ATF4 to promote chemoresistance in gastric Cancer
por: Feng, Lifeng, et al.
Publicado: (2021)

PPARδ, a Potential Therapeutic Target for Heart Disease
por: Yang, Qinglin, et al.
Publicado: (2018)

CK1δ/ε protein kinase primes the PER2 circadian phosphoswitch
por: Narasimamurthy, Rajesh, et al.
Publicado: (2018)

The CK1δ/ε-AES axis regulates tumorigenesis and metastasis in colorectal cancer
por: Wang, Zhongyuan, et al.
Publicado: (2021)

The α2δ-1-NMDA receptor complex and its potential as a therapeutic target for ischemic stroke
por: Wu, Tao, et al.
Publicado: (2023)

CK2 and protein kinases of the CK1 superfamily as targets for neurodegenerative disorders
por: Baier, Andrea, et al.
Publicado: (2022)

Transformation and Characterization of Δ12-Fatty Acid Acetylenase and Δ12-Oleate Desaturase Potentially Involved in the Polyacetylene Biosynthetic Pathway from Bidens pilosa
por: Chen, Po-Yen, et al.
Publicado: (2020)

ΔN-Bcl-xL, a therapeutic target for neuroprotection
por: Park, Han-A, et al.
Publicado: (2017)

PPARδ: A Potential Therapeutic Target for the Treatment of Metabolic Hypertension
por: Jiang, Yanli, et al.
Publicado: (2019)

δ-Opioid receptor as a potential therapeutic target for ischemic stroke
por: Subedi, Kalpana, et al.
Publicado: (2019)

Novel group-based QSAR and combinatorial design of CK-1δ inhibitors as neuroprotective agents
por: Joshi, Kopal, et al.
Publicado: (2016)

Biological and Pharmacological Characterization of Benzothiazole-Based CK-1δ Inhibitors in Models of Parkinson’s Disease
por: Morales-Garcia, José A., et al.
Publicado: (2017)

Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer
por: Bejrananda, Tanan, et al.
Publicado: (2021)

GOLPH3 is a potential therapeutic target and a prognostic indicatior of poor survival in bladder cancer treated by cystectomy
por: Zhang, Qing, et al.
Publicado: (2015)

Macro-CK and CK-BB Contributing to Sham CK-MB Elevation
por: Wada, Yuki, et al.
Publicado: (2017)

Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo
por: Chen, Chun-Han, et al.
Publicado: (2016)

Targeting AKT and CK2 represents a novel therapeutic strategy for SMO constitutive activation‐driven medulloblastoma
por: Yao, Yue‐Liang, et al.
Publicado: (2022)

Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2
por: Spinello, Zaira, et al.
Publicado: (2021)

Site-specific phosphorylation of casein kinase 1 δ (CK1δ) regulates its activity towards the circadian regulator PER2
por: Eng, Gracie Wee Ling, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5ha4imdlavdit0u3mt9bj1n7va